peptide
Larazotide Acetate
moderatePhase 3 Clinical TrialsOral
Tightens seals between gut lining cells, directly addressing leaky gut. Developed for celiac disease but useful for gut barrier problems broadly.
Key facts
- Classification
- Peptide — Seals leaky gut by tightening junctions between intestinal cells.
- Primary benefits
- Gut Health (8/10) · Inflammation (6/10) · Immune Support (4/10)
- Administration
- Oral
- Doses studied
- 0.5-1 mg by mouth 3 times daily before meals. Cycle for 8-12 weeks.
- Evidence strength
- Moderate — 20 peer-reviewed studies
- Stacks well with
- BPC-157, KPV
- Legal status
- Phase 3 Clinical Trials · not prescribable in US
Quick stats
- Type
- Peptide
- Administration
- Oral
- Studies referenced
- 20
- Stacks with
- 2 peptides
- Regulatory
- Phase 3 Clinical Trials
Goal coverage · Larazotide Acetate
🫃 Gut Health8/10
🧊 Inflammation6/10
🛡️ Immune Support4/10
Medical oversight recommendedNot safe during pregnancy· 2 contraindications